Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice
Autore:
Connolly, P; Wheat, LJ; Schnizlein-Bick, C; Durkin, M; Kohler, S; Smedema, M; Goldberg, J; Brizendine, E; Loebenberg, D;
Indirizzi:
Histoplasmosis Reference Lab, Indianapolis, IN 46202 USA Histoplasmosis Reference Lab Indianapolis IN USA 46202 olis, IN 46202 USA Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA Indiana Univ Indianapolis IN USA Sch Med, Dept Med, Indianapolis, IN USA Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA IndianaUniv Indianapolis IN USA Pathol & Lab Med, Indianapolis, IN USA Dept Vet Affairs Hosp, Indianapolis, IN USA Dept Vet Affairs Hosp Indianapolis IN USA irs Hosp, Indianapolis, IN USA Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA Schering Plough Corp Kenilworth NJ USA 07033 st, Kenilworth, NJ 07033 USA
Titolo Testata:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
fascicolo: 10, volume: 44, anno: 2000,
pagine: 2604 - 2608
SICI:
0066-4804(200010)44:10<2604:COANTP>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CAPSULATUM ANTIGEN; FLUCONAZOLE; GAMMA; VIRUS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Connolly, P Histoplasmosis Reference Lab, 1001 W 10th,OPW-430, Indianapolis, IN 46202 USA Histoplasmosis Reference Lab 1001 W 10th,OPW-430 Indianapolis IN USA 46202
Citazione:
P. Connolly et al., "Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice", ANTIM AG CH, 44(10), 2000, pp. 2604-2608

Abstract

A murine model of intratracheally induced histoplasmosis in immunocompromised B6C3F(1) mice was used to evaluate a new triazole antifungal agent, posaconazole. This compound was previously shown to be comparable to amphotericin B and superior to itraconazole for the treatment of histoplasmosis in immunocompetent mice. The current study used mice that were depleted of T lymphocytes by intraperitoneal injection of anti-CD4 and anti-CD8 monoclonal antibodies beginning 2 days before infection and continuing at 5-day intervals until completion of the study. Groups of B6C3F(1) mice that were depleted of CD4 and CD8 T cells were infected with an inoculum of 10(4) Histoplasma capsulatum yeasts. All mice receiving posaconazole at 1 or 0.1 mg/kg of body weight/day, amphotericin B at 2 mg/kg every other day (qod), or itraconazole at 75 mg/kg/day survived to day 29. Only 60% of mice receiving itraconazole at 10 mg/kg/day and none receiving amphotericin B at 0.2 mg/kg qod survived to that date. Fungal burdens were determined at day 14 of infection, 1 day after discontinuation of therapy. Quantitative colony counts and Histoplasma antigen levels in lung and spleen tissues declined following treatment with amphotericin B at 2 mg/kg qod, posaconazole at 5 and 1 mg/kg/day, and itraconazole at 75 mg/kg/day but not in mice treated with amphotericin B at 0.2 mg/kg god or itraconazole at 10 mg/kg/day. Posaconazole at 0.1 mg/kg/day reduced fungal colony counts and antigen levels in spleens but not in lungs. This study shows posaconazole activity for the treatment of histoplasmosis in immunosuppressed animals.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 15:07:03